Alzheimer's Disease Research Center- Supplement 3.1- Anthony Briggs 2022

阿尔茨海默病研究中心 - 补充 3.1 - 安东尼·布里格斯 2022

基本信息

批准号：
10610057
负责人：
THOMAS M WISNIEWSKI
金额：
$ 11.98万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-01 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10610057
关键词：
Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Amyloid Area Autopsy Behavioral Biological Assay Biological Markers Cerebrospinal Fluid Clinical Clinical Data Cognitive Collaborations Communities Counseling Cyclotrons Data Linkages Data Set Dementia Development Diagnosis Diagnostic Services Early Diagnosis Education Fostering Funding Goals Health Heterogeneity Impaired cognition Infrastructure Intervention Investigation Laboratories Magnetic Resonance Imaging Measures Mental Depression Methodology Mission Neuropsychology New York Participant Pathology Patients Performance Phenotype Plasma Population Positron-Emission Tomography Proteomics Psychological Impact Radiochemistry Research Role Scanning Scientist Secure Statistical Data Interpretation Stress Techniques Therapeutic Intervention Time Training Training and Education Translational Research Universities Update Work aged aging brain biomarker development cognitive function cognitive testing community setting data management disease heterogeneity education research epidemiology study improved in vivo induced pluripotent stem cell innovation mild cognitive impairment neuroimaging neuroimaging marker neuropathology next generation normal aging novel novel marker novel therapeutic intervention outreach posters prevent programs psychosocial recruit social factors sociodemographic variables tau Proteins therapeutically effective

项目摘要

Since its inception in 1990, the Alzheimer's Disease Research Center (ADRC) at New York University Langone Health has facilitated pioneering research to define transitions from normal aging to the subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early dementia stages of AD; as well as AD biomarker development. Here we propose to continue this long-standing successful research direction with a focus on understanding disease heterogeneity and delineating biomarkers and their role in these transitions, with the long-term goal of helping to develop novel interventions that will delay or prevent cognitive decline. The NYU ADRC has built an infrastructure that supports innovative research on AD and related dementias (ADRD) to help achieve the NAPA goal of a cure by 2025. This will be facilitated by our nine highly successful and interactive Cores (Admin; Clinical; Data Management & Statistical [DMS]; Neuropathology; Outreach, Education & Engagement [ORE]; Neuroimaging; Biomarker; Psychosocial; and Research Education Component [REC]). Together, our highly integrated cores will achieve the following aims: Aim 1. Enhance the performance of innovative research in ADRC by maintaining nine cores that focus on delineating biomarkers of the transitions from normal aging to SCD, MCI, and early dementia, and determining their roles to help develop novel interventions that delay or prevent these transitions. We will also facilitate training in this area. Aim 2. Contribute to the national network of ADRCs by providing clinical data, autopsy diagnoses, neuroimaging and biosamples to NACC and NCRAD, as well as to other research community collaborative efforts in ADRD. Aim 3. Recruit and retain a diverse subject population from clinical and community settings, via the ORE and Psychosocial Cores, with concomitant engagement of the local scientific and lay community in ADRD with seminars, poster sessions and the developmental projects via the Admin, ORE, and REC Cores. Aim 4. Foster the development of novel avenues of investigation with methodological developments by the cores (via innovative cognitive assessments, neuroimaging techniques, biomarkers and proteomic approaches), and encourage, recruit, and select developmental projects. Aim 5. Accelerate translational research across the ADRD spectrum by using biomarkers to better define the underlying disease heterogeneity and foster the development of novel therapeutic interventions that consider this heterogeneity. Aim 6. Facilitate the education and training of a diverse ADRD workforce. Our Center will enhance the scientific community's understanding of ADRD and expand the next generation of diverse ADRD scientists, via combined efforts of the Admin, ORE, and REC Cores. In summary, the NYU ADRD has facilitated pioneering research that defined the stage transitions from normal aging to dementia, and contributed to AD biomarker development from its inception. In the next five years of funding, this focus will be expanded by: 1) improving our understanding of disease heterogeneity; 2) identifying new biomarkers that will allow early detection; and 3) fostering research that will develop effective therapeutic interventions.

纽约大学朗格尼分校阿尔茨海默病研究中心 (ADRC) 自 1990 年成立以来健康促进了开创性研究，以定义从正常衰老到主观认知的转变 AD 的衰退（SCD）、轻度认知障碍（MCI）和早期痴呆阶段；以及 AD 生物标志物发展。在这里，我们建议继续这一长期成功的研究方向，重点是了解疾病异质性并描述生物标志物及其在这些转变中的作用，长期目标是帮助开发新的干预措施，以延缓或防止认知能力下降。纽约大学 ADRC 建立了支持 AD 和相关痴呆症创新研究的基础设施 (ADRD) 帮助实现 NAPA 到 2025 年治愈的目标。我们的九个非常成功的项目将促进这一目标和互动核心（管理；临床；数据管理和统计 [DMS]；神经病理学；外展，教育与参与[ORE]；神经影像学；生物标志物；社会心理；和研究教育部分 [记录]）。我们高度集成的内核将共同实现以下目标：目标 1. 增强性能 ADRC 的创新研究通过维护九个核心来重点描述转变的生物标志物从正常衰老到 SCD、MCI 和早期痴呆，并确定它们的作用以帮助开发新的延迟或阻止这些转变的干预措施。我们还将促进这方面的培训。目标 2. 贡献通过提供临床数据、尸检诊断、神经影像和生物样本，向国家 ADRC 网络提供信息感谢 NACC 和 NCRAD，以及 ADRD 中其他研究界的合作努力。目标 3. 招募和通过 ORE 和心理社会核心，保留来自临床和社区环境的多样化受试者群体， ADRD 当地科学界和非专业界人士同时参与研讨会、海报会议以及通过 Admin、ORE 和 REC 核心进行的开发项目。目标4.促进小说发展核心研究方法论发展的途径（通过创新的认知评估，神经影像技术、生物标志物和蛋白质组学方法），并鼓励、招募和选择发展项目。目标 5. 通过使用加速整个 ADRD 谱系的转化研究生物标志物可以更好地定义潜在的疾病异质性并促进新疗法的开发考虑到这种异质性的干预措施。目标 6. 促进多元化 ADRD 的教育和培训劳动力。我们中心将增强科学界对 ADRD 的理解，并拓展未来的研究方向通过 Admin、ORE 和 REC 核心的共同努力，培养了一批多元化的 ADRD 科学家。总之，纽约大学 ADRD 促进了开创性研究，定义了从正常衰老到衰老的阶段过渡痴呆症，并从一开始就为 AD 生物标志物的开发做出了贡献。在未来五年的资金投入中，重点将通过以下方式扩大：1）提高我们对疾病异质性的理解； 2) 识别新的生物标志物这将有助于及早发现； 3) 促进研究以开发有效的治疗干预措施。